Galmed pulls off $38M IPO for NASH drug; Venaxis leaps on appendicitis results;

@FierceBiotech: Sage snags $38M from A-list VCs to bankroll its seizure drugs. More | Follow @FierceBiotech

@JohnCFierce: Circassia's record-busting $332M IPO inspires hopes of U.K. renaissance. News | Follow @JohnCFierce

@DamianFierce: Vectura bags respiratory biotech Activaero for $181M. Story | Follow @DamianFierce

@EmilyMFierce: Despite progress, tuberculosis persists in West European cities. Piece via Reuters | Follow @EmilyMFierce

> Galmed Pharmaceuticals ($GLMD) landed $38 million in a mid-range IPO, raising cash to fund its in-development treatment for nonalcoholic steatohepatitis (NASH). Story

> Venaxis ($APPY) watched its shares climb more than 25% on news that its appendicitis diagnostic performed well in a clinical trial. News

Medical Device News

@FierceMedDev: Add debt restructuring to Quest Diagnostics' numerous moves to improve things. Story | Follow @FierceMedDev

@MarkHFierce: Philips ventilator recall gets slapped with the FDA's Class I recall status--its most serious designation. More | Follow @MarkHFierce

@MichaelGFierce: NeuroDerm preps for Parkinson's patch PhII trial. Read in FierceDrugDelivery. | Follow @MichaelGFierce

@EmilyWFierce: Roche gets glowing reviews from FDA panel for frontline HPV test. Article | Follow @EmilyWFierce

> Quest Diagnostics is proposing a $600M debt refinancing. More

> Vaginal mesh lawsuits are escalating in Scotland. Piece

Pharma News

@FiercePharma: Yesterday's top-read special report: The top 10 pharma companies by 2013 revenue. Read | Follow @FiercePharma

@TracyStaton: Uh-oh for Merck animal health: Hundreds more Zilmax-fed cattle died than Merck reported to FDA. Story via Reuters | Follow @TracyStaton

@EricPFierce: Sun Pharma plant joins FDA village of the banned. Story via FiercePharmaManufacuring | Follow @EricPFierce

@CarlyHFierce: Missed yesterday's issue of FiercePharmaMarketing? Got you covered. | Follow @CarlyHFierce

> Pfizer's billion-dollar Celebrex patent loss has Mylan, Actavis revving up generics. Article

> High court dashes Actelion's hopes for $407M reprieve in Tracleer case. More

Pharma Manufacturing News

> CMO born from $2.6 billion merger comes on the scene as DPx. Story

> Sun Pharma plant joins the FDA list of banned Indian facilities. News

> FDA says Indian drugmaker made up data for API tests. Piece

> Bayer expands German plants as it preps for new hemophilia treatments. More

> Hikma hits the jackpot with doxycycline shortage. Coverage

> Pharma cargo theft takes new spike. Brief

Vaccines News

> Daiichi misses H5N1 vaccine production goal after low yields slash output. Story

> Analysts offer mixed reactions to Pfizer's Prevnar 13 data close-up. Article

> Northwest Bio, NewLink proceed with cancer vax trials to mixed reviews. News

> ImmusanT waits on early clinical data for its celiac disease vaccine. Story

> Study: Vaccinating diabetics against flu cuts risk of death by 28%. Article

> U.K. mulls adopting a 2-dose model for HPV vaccination. Brief

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.